Recent Comments

  • Tina: 看冬蕾老师的文章已成习惯,感谢点点滴滴的温暖。
  • 择偶网: 新冠快点结束吧!
  • 淼淼: 一向觉得这种背影特别有爱……
  • 淼淼: 十年前的回忆!毛毛太棒啦,粉丝又多了一枚!拥有这么有才情的辣妈,月月童鞋是有多幸福……
  • DJ: Don’t comment on China’s regulatory environment –if you have to, positive and complementary remarks are always expected; i don't think so...
  • DJ: 就假装他们都很伟大....
  • DJ: 赞一个

Random Posts

Tag Cloud

Paul Pomerantz:关于创新的探讨应该有中国的声音

2010/03/17 – 5:04 下午

根据美国药物信息协会(DIA)的全球执行董事Paul Pomerantz的回答,我写了一篇很扯的人物对话稿。


Q: what do you think of the first DIA China annual meeting?  How do you rate it given the 100 points scale? What’s your impression to China?

A:The first DIA China annual meeting was a total success.  100 on a scale of 100.  The meeting enjoyed support at the highest levels of the SFDA and gained worldwide recognition thought the participation of regulators internationally including those from the FDA, EMEA and PMDA.  We believe China is a significant player in size and influence in both drug development and discovery.  I have been very impressed by the enthusiasm of both government and industry leaders.  China has a clear commitment to innovation, quality and leadership in the development of pharmaceutical and related products.

Q: Could you share with us your career story? what’s your best achievements till now? Is there any experience that can be taken as a turning point for your life?

A:My professional degree is in healthcare administration.  I have worked in government, health care delivery (as a hospital administrator) and as a health care association executive.  As an association executive, I have led international organizations serving clinical laboratory, radiology, plastic surgery and now pharmaceutical and medical product executives.  There were three major professional turning points for me.  My first “turning point” came in 1990 when I first became an association leader and learned of the tremendous impact associations can have on motivating and educating professionals. The second was in 1997 when the organization I was working with (Clinical Laboratory Management Association) succeeded in advancing legislation mandating an Institute of Medicine Study on laboratory payment.  This affirmed for me the power of associations to develop public policy.  The third came in my position with the Society of Interventional Radiology, when we were approached by the FDA to coordinate a post market study with several manufacturers involving a specific device.  This milestone, which is often cited by the FDA as a model of private-public partnership, conveyed to me the power of collaboration and science.  The study, which was very successful, was overseen by a steering group consisting of radiologists, consumers, FDA, industry representatives and health service researchers.

Q:In the past years, is there anyone or anything that brings a major influence to your life?

A:I feel many have influenced me as mentors or as role models.  There have been some bosses, early in my career, who taught me the importance of vision and setting high standards, treating people well, hard work, leading teams to develop creative solutions to complex problems and execute projects, and concern for the patient and customer.

Q: Why did you join in DIA? Currently, what’s your focus and challenge in your work? What’s your expectation to yourself?

A:I was attracted by DIA’s mission,  excited by our vision, and impressed by all the DIA leaders and members I met.    The global nature of pharmaceutical (and related product) development and regulation, and the global challenge of health care costs, public health concerns (including pandemics, neglected diseases, and those of developing and developed nations) represent opportunities that can be best addressed through DIA’s neutral, multi-disciplinary stakeholder forum.  I think DIA can truly make a difference to improve health care delivery and health status world wide.

My major focus at this time is aligning the organization to function more effectively as a global organization, to upgrade our technology to support our members around the world, to build awareness of DIA by those who might not be familiar with us, and to update our offerings consistent with changes in the health system.

Q: You once said, “drug is not only making medicines”, when you were elected to be the president of DIA, could you share your points of drug development? How to meet the unmet clinical needs with patient oriented?

A:Two key points: First, our world has expanded from drugs to “life sciences” and includes a range of regulated medical products that range from drugs, to biologics and bio-similars, to diagnostics and personalized medicine.  Second, regulators in many countries, and thus companies, have expanded their focus from product approvals to post approval aspects including safety, technology assessment, and pricing. As a result, information technology, particularly electronic medical records and registries are playing an increasing role in DIA’s programs.

DIA has four key pillars: industry, regulators, academia, and to an increasing degree, patients.  These are represented in many DIA regions by patient organization representatives who participate as part of governance (helping set direction) and in programs.  At DIA, as for the industry and the regulators, the voice of the patient is becoming increasingly important.  Their key concerns include innovation to treat neglected diseases, improvements to current treatment and safety.

Q: Last year, DIA set up its office in China, what’s your strategy here in China? What’s your expectation to China market given its unique healthcare system and pharmaceutical industry?

A:DIA’s strategy in China is to support its national needs as identified by our advisory council.  Our advisory council includes those from regulatory (CCPIE/SFDA), multinational industry and contract research organizations, and the domestic pharmaceutical industry.  While we will make all our benefits including our peer reviewed journal available to our members in China, we have just signed an agreement with the CPA to develop a joint Chinese language newsletter, to explore additional joint programs, and expand awareness across both organizations.

We want to work with our volunteers and members in China to serve the nation to the greatest degree possible and to help facilitate its participation regionally and globally.

Q: With more and more MNCs set up its R&D center today in China, China begin to play a big role in new drug development globally, what do you think of this? What’s the strength and weakness of China compared with India in this area?

A:China has the talent and capacity to play a major role in drug development.  As a neutral organization, DIA is committed to support drug development wherever the need is.

Q: How do you comment yourself? what’s your principle as a teamleader?

A:My principle as a team leader is inclusion and participation.  I like to surround myself with the most talented, experienced, and dedicated people.  My job is not to have the answers, but to lead a group that, with good decision making, can come up with the best answers.

Q:Could you talk something about your dreams?what’s the present dream for you now?

A:Family is very important to me.  I spend much time with my grown children.  My son is married and has a 16 month old daughter who I love to watch grow.  I am also close to my own daughter who is a professional chef and caterer. I enjoy my work a great deal, but I would also like to mentor and teach others the skills to lead complex organizations.


他的身边聚拢着一大批 “充满才情,富有经验和专注”的志愿者,他们来自全球各国,有着不同颜色的皮肤和眼睛,职位几乎毫无例外是跨国制药研发系统跨洲际的总监总裁级别。而被来自中国志愿者们亲切的称为“头儿”的Paul Pomerantz先生,头发花白,笑容可掬,一如美国药物信息协会(Drug Information Association,DIA)中国顾问委员会的成员们在记者面前留下的印象,轻松、平等、合作、专业。

作为全球最大非营利性科研型协会美国药物信息协会的全球执行董事,Paul Pomerantz负责实施协会的战略计划并指导DIA的全球运作。他拥有30年的行政管理经验,并在健康政策、医学会管理和保健管理方面拥有专长。


对于国内制药行业尚显陌生的美国DIA, Pomerantz在讲述他个人经历之前,谈得更多是他对与药物研发、患者需求以及人与人之间的相互理解与和谐共处。而我们的对话也从去年DIA首次在中国举办第一届中国年会谈起。

2009年11月, DIA第一届中国年会在大雪纷飞的北京举行。首次中国年会的召开,对于创新型转型下的中国制药行业带了不同寻常的意义。2010年初春的北京,Pomerantz再次来到北京。












问: 您上任DIA全球总裁的时候,曾说过“drug is not only making medicines”,能否诠释一下您对药物开发的理解?如何以患者为导向满足临床上未被满足的需求?

Pomerantz:随着现代科学技术的发展,药学科学已分为两个主要领域:一是以药物为导向,以研究和生产药物为目标的药学(drug oriented pharmacy),主要以化学、生物学、医学和工程技术等自然科学为基础。主要任务是研究、发明和生产为疾病预防、治疗和检查诊断所需要的安全、有效、经济的药物。二是以患者和社会为导向(patient and social-oriented pharmacy),以研究药物的适当提供和合理使用为目标的药学,它的任务是研究药物的使用,监督和组织协调药物、患者和社会之间的关系。




Pomerantz: DIA 在中国的策略是根据我们的顾问委员会确定的在中国的需求,支持对中国药品研发、监管、使用诸方面有帮助的活动,我们将和中国的有关监管部门、创新研发单位、国内企业、大学院校开展密切的交流和互利的合作。DIA的会员和志愿者也将努力促进中国相关部门和业界人士与其他国家和地区的同行交流和合作。





Pomerantz: 作为一个团队的领导人,他必须具有很强的包容性,他要参与整个团队的建设和成长。必须时刻激发和激励和你共事的人在面对各种复杂多变的问题面前必须保持坚定的信念,并具有创造力的解决他们。而置身于与健康、药品相关的产业,对病人怀有一颗充满爱和怜悯之心是必须的。







XHTML: You can use these tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>